Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

NURO

NeuroMetrix (NURO)

NeuroMetrix Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NURO
DateHeureSourceTitreSymboleSociété
31/05/202419h15Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:NURONeuroMetrix Inc
24/05/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NURONeuroMetrix Inc
15/05/202422h00GlobeNewswire Inc.NeuroMetrix Reports Q1 2024 Business HighlightsNASDAQ:NURONeuroMetrix Inc
15/05/202418h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NURONeuroMetrix Inc
15/05/202417h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NURONeuroMetrix Inc
19/04/202414h00GlobeNewswire Inc.NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNASDAQ:NURONeuroMetrix Inc
14/03/202414h00GlobeNewswire Inc.NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNASDAQ:NURONeuroMetrix Inc
13/03/202414h00GlobeNewswire Inc.NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNASDAQ:NURONeuroMetrix Inc
04/03/202422h12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NURONeuroMetrix Inc
01/03/202423h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NURONeuroMetrix Inc
27/02/202422h45Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NURONeuroMetrix Inc
27/02/202422h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NURONeuroMetrix Inc
22/02/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NURONeuroMetrix Inc
22/02/202413h00GlobeNewswire Inc.NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/02/202420h49Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NURONeuroMetrix Inc
15/02/202415h00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
13/02/202415h00GlobeNewswire Inc.NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNASDAQ:NURONeuroMetrix Inc
12/12/202315h00GlobeNewswire Inc.NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)NASDAQ:NURONeuroMetrix Inc
05/12/202315h00GlobeNewswire Inc.NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)NASDAQ:NURONeuroMetrix Inc
20/11/202315h00GlobeNewswire Inc.NeuroMetrix Announces One-for-Eight Reverse Stock SplitNASDAQ:NURONeuroMetrix Inc
26/10/202313h00GlobeNewswire Inc.NeuroMetrix Reports Q3 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
23/10/202317h13GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
02/10/202315h00GlobeNewswire Inc.NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaNASDAQ:NURONeuroMetrix Inc
11/09/202313h59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NURONeuroMetrix Inc
27/07/202313h00GlobeNewswire Inc.NeuroMetrix Reports Q2 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/07/202319h00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
11/07/202315h00GlobeNewswire Inc.NeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaNASDAQ:NURONeuroMetrix Inc
28/06/202315h00GlobeNewswire Inc.Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsNASDAQ:NURONeuroMetrix Inc
07/06/202315h00GlobeNewswire Inc.Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyNASDAQ:NURONeuroMetrix Inc
31/05/202323h22Edgar (US Regulatory)Specialized Disclosure Report (sd)NASDAQ:NURONeuroMetrix Inc
 Showing the most relevant articles for your search:NASDAQ:NURO